地拉罗司2020年多少钱一盒？

(Enrig) ​​is a tridentate iron chelator that combines with ferric ions at a ratio of 2:1 to form a complex, which is excreted in the feces, thereby reducing iron storage in the body. Due to the continued presence of Deferasirox (Enrige) in plasma, plasma non-transferrin-bound iron can be continuously reduced and the iron formed by toxicity in the body can be directly removed. Today we will learn more about how much does a box of deferasirox cost in 2020?

In 2010, Deferasirox (Enrige) was approved for marketing in China. According to Medical Companion Travel, Deferasirox has not been officially included in medical insurance and is a self-pay drug for patients. Deferasirox India Cipla Desirox 500mg*30 tablets is around 240$. Swiss Novartis Asunra 400mg*30 tablets is around 420$. Patients in need can purchase drugs abroad or obtain drugs through domestic professional overseas medical service organizations (such as Medical Companion Travel), which are guaranteed to be genuine.

   

Deferasirox (Enrige) has been on the market in the United States for 10 years after its development and is the most prescribed iron chelator. Deferasirox, a new oral formulation from Exjade, is the first directly swallowable once-daily oral iron chelator. Exjade is a dispersible tablet that must be mixed with liquid and taken on an empty stomach at least 30 minutes before meals. Deferasirox can be swallowed directly with or without a light meal, greatly simplifying the treatment and management of chronic iron overload (CIO).

The indications of the new drug Deferasirox (Enriga) approved by the US FDA are: (1) for the treatment of chronic iron overload (CIO) caused by blood transfusion in patients 2 years old and above; (2) for the treatment of chronic iron overload (CIO) in patients 10 years old and above with non-transfusion-dependent thalassemia syndrome (NTDT).

According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS. During the 3-year study, 138 (79.8%) patients discontinued treatment, 43 (24.8%) of whom discontinued treatment due to adverse events or disease progression, and 23 (13.2%) due to abnormal laboratory test values. The most common drug-related adverse events were gastrointestinal disturbances and increased serum creatinine. Twenty-eight patients died, but none were related to deferasirox treatment.

The results of this trial show that deferasirox (Enrige) can reduce serum ferritin and LPI in transfusion-dependent MDS patients, and some patients' hemogram and liver function can be improved to a certain extent.

The above is the price content of (Enrig), I hope it can help you!

Recommended related hot articles: /newsDetail/80679.html